Longeveron (NASDAQ:LGVN – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
10.0% of Longeveron shares are held by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. 19.1% of Longeveron shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Longeveron and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -2,129.24% | -300.96% | -164.96% |
| MoonLake Immunotherapeutics | N/A | -7.92% | -7.76% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.23 million | 12.30 | -$21.41 million | ($9.61) | -0.25 |
| MoonLake Immunotherapeutics | N/A | N/A | -$36.01 million | ($0.75) | -63.87 |
Longeveron has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Longeveron has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Longeveron and MoonLake Immunotherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 0 | 0 | 1 | 0 | 3.00 |
| MoonLake Immunotherapeutics | 0 | 4 | 9 | 0 | 2.69 |
Longeveron currently has a consensus price target of $10.00, suggesting a potential upside of 321.94%. MoonLake Immunotherapeutics has a consensus price target of $78.67, suggesting a potential upside of 63.34%. Given Longeveron’s stronger consensus rating and higher possible upside, research analysts plainly believe Longeveron is more favorable than MoonLake Immunotherapeutics.
Summary
MoonLake Immunotherapeutics beats Longeveron on 7 of the 13 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
